Clinical Significance Linked to Functional Defects in Bone Morphogenetic Protein Type 2 Receptor, BMPR2

Overview

Journal BMB Rep

Specialties Biochemistry
Molecular Biology

Date 2017 Apr 11

PMID 28391780

Citations 13

Authors

Myung-Jin Kim

Seon Young Park

Hae Ryung Chang

Eun Young Jung

Anudari Munkhjargal

Jong-Seok Lim

Myeong-Sok Lee

YongHwan Kim

Affiliations

Soon will be listed here.

Abstract

Bone morphogenetic protein type 2 receptor (BMPR2) is one of the transforming growth factor-β (TGF-β) superfamily receptors, performing diverse roles during embryonic development, vasculogenesis, and osteogenesis. Human BMPR2 consists of 1,038 amino acids, and contains functionally conserved extracellular, transmembrane, kinase, and C-terminal cytoplasmic domains. Bone morphogenetic proteins (BMPs) engage the tetrameric complex, composed of BMPR2 and its corresponding type 1 receptors, which initiates SMAD proteins-mediated signal transduction leading to the expression of target genes implicated in the development or differentiation of the embryo, organs and bones. In particular, genetic alterations of BMPR2 gene are associated with several clinical disorders, including representative pulmonary arterial hypertension, cancers, and metabolic diseases, thus demonstrating the physiological importance of BMPR2. In this mini review, we summarize recent findings regarding the molecular basis of BMPR2 functions in BMP signaling, and the versatile roles of BMPR2. In addition, various aspects of experimentally validated pathogenic mutations of BMPR2 and the linked human diseases will also be discussed, which are important in clinical settings for diagnostics and treatment. [BMB Reports 2017; 50(6): 308-317].

Citing Articles

Emerging role of BMPs/BMPR2 signaling pathway in treatment for pulmonary fibrosis.

Ye Q, Taleb S, Zhao J, Zhao Y Biomed Pharmacother. 2024; 178:117178.

PMID: 39142248 PMC: 11364484. DOI: 10.1016/j.biopha.2024.117178.

Switch-Independent 3A: An Epigenetic Regulator in Cancer with New Implications for Pulmonary Arterial Hypertension.

Jankowski K, Jagana V, Bisserier M, Hadri L Biomedicines. 2024; 12(1).

PMID: 38275371 PMC: 10813728. DOI: 10.3390/biomedicines12010010.

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in -Rearranged Acute Lymphoblastic Leukemia.

Schneider P, Wander P, Arentsen-Peters S, Vrenken K, Rockx-Brouwer D, Adriaanse F Int J Mol Sci. 2023; 24(17).

PMID: 37686014 PMC: 10487613. DOI: 10.3390/ijms241713207.

Pathogenesis of pulmonary hypertension caused by left heart disease.

Xiao M, Lai D, Yu Y, Wu Q, Zhang C Front Cardiovasc Med. 2023; 10:1079142.

PMID: 36937903 PMC: 10020203. DOI: 10.3389/fcvm.2023.1079142.

Variants Underlie Nonsyndromic Oligodontia.

Zheng J, Liu H, Yu M, Lin B, Sun K, Liu H Int J Mol Sci. 2023; 24(2).

PMID: 36675162 PMC: 9860601. DOI: 10.3390/ijms24021648.

References

Razzouk S, Sarkis R . BMP-2: biological challenges to its clinical use. N Y State Dent J. 2012; 78(5):37-9. View

Kanakaris N, Giannoudis P . Clinical applications of bone morphogenetic proteins: current evidence. J Surg Orthop Adv. 2008; 17(3):133-46. View

Harper R, Reynolds A, Bonder C, Reynolds P . BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling. Respirology. 2016; 21(4):727-33. DOI: 10.1111/resp.12729. View

Wiley D, Jin S . Bone Morphogenetic Protein functions as a context-dependent angiogenic cue in vertebrates. Semin Cell Dev Biol. 2011; 22(9):1012-8. PMC: 3548572. DOI: 10.1016/j.semcdb.2011.10.005. View

Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney J, Rosen V . The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun. 1990; 172(1):295-9. DOI: 10.1016/s0006-291x(05)80208-6. View

Atkinson C, Stewart S, Upton P, Machado R, Thomson J, Trembath R . Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002; 105(14):1672-8. DOI: 10.1161/01.cir.0000012754.72951.3d. View

Sieber C, Kopf J, Hiepen C, Knaus P . Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009; 20(5-6):343-55. DOI: 10.1016/j.cytogfr.2009.10.007. View

Hamid R, Hedges L, Austin E, Phillips 3rd J, Loyd J, Cogan J . Transcripts from a novel BMPR2 termination mutation escape nonsense mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension. Clin Genet. 2010; 77(3):280-6. PMC: 3741656. DOI: 10.1111/j.1399-0004.2009.01311.x. View

Wiley D, Kim J, Hao J, Hong C, Bautch V, Jin S . Distinct signalling pathways regulate sprouting angiogenesis from the dorsal aorta and the axial vein. Nat Cell Biol. 2011; 13(6):686-92. PMC: 3107371. DOI: 10.1038/ncb2232. View

10.

Howe J, Bair J, Sayed M, Anderson M, Mitros F, Petersen G . Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet. 2001; 28(2):184-7. DOI: 10.1038/88919. View

11.

Yoon B, Ovchinnikov D, Yoshii I, Mishina Y, Behringer R, Lyons K . Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc Natl Acad Sci U S A. 2005; 102(14):5062-7. PMC: 555995. DOI: 10.1073/pnas.0500031102. View

12.

Wu N, Zhao Y, Yin Y, Zhang Y, Luo J . Identification and analysis of type II TGF-β receptors in BMP-9-induced osteogenic differentiation of C3H10T1/2 mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai). 2010; 42(10):699-708. DOI: 10.1093/abbs/gmq075. View

13.

Katagiri T, Imada M, Yanai T, Suda T, Takahashi N, Kamijo R . Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells. 2002; 7(9):949-60. DOI: 10.1046/j.1365-2443.2002.00573.x. View

14.

Park S, Hur S, Yoo N, Lee S . Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability. APMIS. 2010; 118(11):824-9. DOI: 10.1111/j.1600-0463.2010.02670.x. View

15.

Hogan B . Bone morphogenetic proteins in development. Curr Opin Genet Dev. 1996; 6(4):432-8. DOI: 10.1016/s0959-437x(96)80064-5. View

16.

Franzen A, Piek E, Westermark B, Ten Dijke P, Heldin N . Expression of transforming growth factor-beta1, activin A, and their receptors in thyroid follicle cells: negative regulation of thyrocyte growth and function. Endocrinology. 1999; 140(9):4300-10. DOI: 10.1210/endo.140.9.6961. View

17.

Zhang D, Mehler M, Song Q, Kessler J . Development of bone morphogenetic protein receptors in the nervous system and possible roles in regulating trkC expression. J Neurosci. 1998; 18(9):3314-26. PMC: 6792660. View

18.

Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T . BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol. 2000; 221(1):249-58. DOI: 10.1006/dbio.2000.9670. View

19.

Finkenzeller G, Hager S, Stark G . Effects of bone morphogenetic protein 2 on human umbilical vein endothelial cells. Microvasc Res. 2012; 84(1):81-5. DOI: 10.1016/j.mvr.2012.03.010. View

20.

Lee K, Tsai K, Wang N, Ingber D . Extracellular matrix and pulmonary hypertension: control of vascular smooth muscle cell contractility. Am J Physiol. 1998; 274(1):H76-82. DOI: 10.1152/ajpheart.1998.274.1.H76. View